The AT(N) framework for Alzheimer's disease in adults with Down syndrome
Rafii, Michael S. (University of Southern California)
Ances, Beau M. (Washington University School of Medicine in St. Louis)
Schupf, Nicole (Columbia University Medical Center)
Krinsky-McHale, Sharon J. (NYS Institute for Basic Research in Developmental Disabilities)
Mapstone, Mark (University of California)
Silverman, Wayne (University of California)
Lott, Ira (University of California)
Klunk, Willian (University of Pittsburgh)
Head, Elizabeth (University of California)
Christian, Brad (University of Wisconsin Madison)
Lai, Florence (Massachusetts General Hospital (Boston))
Rosas, H.Diana (Harvard Medical School)
Zaman, Shahid (Cambridgeshire and Peterborough NHS Foundation Trust)
Petersen, Melissa E. (University of North Texas Health Science Center)
Strydom, Andre (King's College London)
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau)
Handen, Benjamin (University of Pittsburgh)
O'Bryant, Sid (University of North Texas Health Science Center)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	The National Institute on Aging in conjunction with the Alzheimer's Association (NIA-AA) recently proposed a biological framework for defining the Alzheimer's disease (AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms. By using these same biomarkers, individuals with Down syndrome (DS), who are genetically predisposed to developing AD, can also be placed more precisely along the AD continuum. The A/T(N) framework is therefore thought to provide an objective manner by which to select and enrich samples for clinical trials. This new framework is highly flexible and allows the addition of newly confirmed AD biomarkers into the existing AT(N) groups. As biomarkers for other pathological processes are validated, they can also be added to the AT(N) classification scheme, which will allow for better characterization and staging of AD in DS. These biological classifications can then be merged with clinical staging for an examination of factors that impact the biological and clinical progression of the disease. Here, we leverage previously published guidelines for the AT(N) framework to generate such a plan for AD among adults with DS.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, Vol. 12 Núm. 1 (2020) , p. e12062, ISSN 2352-8729

DOI: 10.1002/dad2.12062
PMID: 33134477

10 p, 497.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles